Zegerid Patent Expiration

Zegerid is a drug owned by Salix Pharmaceuticals Inc. It is protected by 7 US drug patents filed from 2013 to 2014 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 16, 2016. Details of Zegerid's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6699885 Substituted benzimidazole dosage forms and methods of using same
Jul, 2016

(8 years ago)

Expired
US6645988 Substituted benzimidazole dosage forms and method of using same
Jul, 2016

(8 years ago)

Expired
US6489346 Substituted benzimidazole dosage forms and method of using same
Jul, 2016

(8 years ago)

Expired
US5840737 Omeprazole solution and method for using same
Jul, 2016

(8 years ago)

Expired
US6780882 Substituted benzimidazole dosage forms and method of using same
Jul, 2016

(8 years ago)

Expired
US7399772 Substituted benzimidazole dosage forms and method of using same
Jul, 2016

(8 years ago)

Expired
USRE45198 Omeprazole solution and method for using same
Jul, 2016

(8 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Zegerid's patents.

Given below is the list of recent legal activities going on the following patents of Zegerid.

Activity Date Patent Number
Patent litigations
Correspondence Address Change 03 Nov, 2005 US6780882
Correspondence Address Change 28 Oct, 2005 US6780882
File Marked Found 23 Mar, 2005 US6780882
Correspondence Address Change 11 Mar, 2005 US6780882
File Marked Lost 04 Mar, 2005 US6780882
Correspondence Address Change 11 Nov, 2004 US6780882
Correspondence Address Change 27 Oct, 2004 US6780882
Patent Issue Date Used in PTA Calculation 24 Aug, 2004 US6780882
Recordation of Patent Grant Mailed 24 Aug, 2004 US6780882
Issue Notification Mailed 05 Aug, 2004 US6780882

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Zegerid is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Zegerid's family patents as well as insights into ongoing legal events on those patents.

Zegerid's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Zegerid's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 16, 2016 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Zegerid Generics:

There are no approved generic versions for Zegerid as of now.

How can I launch a generic of Zegerid before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Zegerid's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Zegerid's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Zegerid -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
20 mg/1100 mg and 40 mg/1100 mg 30 Apr, 2007 1 25 May, 2010 16 Jul, 2016 Eligible
20mg/1680mg per packet 13 Nov, 2007 1 19 Apr, 2013 16 Jul, 2016 Deferred
40 mg/1680 mg per packet 24 Aug, 2007 1 19 Apr, 2013 16 Jul, 2016 Deferred

Alternative Brands for Zegerid

Zegerid which is used for treatment of upper gastrointestinal issues including ulcers, GERD symptoms, and maintenance of esophagitis healing., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Azurity
Konvomep Used for reducing the risk of upper gastrointestinal bleeding and short-term treatment of active benign gastric ulcers in critically ill patients.
Santarus
Magnesium Hydroxide And Omeprazole And Sodium Bicarbonate Used for treating various gastrointestinal conditions such as ulcers, heartburn, and GERD.





About Zegerid

Zegerid is a drug owned by Salix Pharmaceuticals Inc. It is used for treatment of upper gastrointestinal issues including ulcers, GERD symptoms, and maintenance of esophagitis healing. Zegerid uses Omeprazole; Sodium Bicarbonate as an active ingredient. Zegerid was launched by Salix in 2004.

Approval Date:

Zegerid was approved by FDA for market use on 15 June, 2004.

Active Ingredient:

Zegerid uses Omeprazole; Sodium Bicarbonate as the active ingredient. Check out other Drugs and Companies using Omeprazole; Sodium Bicarbonate ingredient

Treatment:

Zegerid is used for treatment of upper gastrointestinal issues including ulcers, GERD symptoms, and maintenance of esophagitis healing.

Dosage:

Zegerid is available in the following dosage forms - for suspension form for oral use, capsule form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
40MG/PACKET;1.68GM/PACKET FOR SUSPENSION Discontinued ORAL
20MG;1.1GM CAPSULE Discontinued ORAL
40MG;1.1GM CAPSULE Discontinued ORAL
20MG/PACKET;1.68GM/PACKET FOR SUSPENSION Discontinued ORAL


Zegerid Patent Expiration

Zegerid is a drug owned by Santarus Inc. It is protected by 4 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 16, 2016. Details of Zegerid's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7399772 Substituted benzimidazole dosage forms and method of using same
Jul, 2016

(8 years ago)

Expired
US6699885 Substituted benzimidazole dosage forms and methods of using same
Jul, 2016

(8 years ago)

Expired
US6489346 Substituted benzimidazole dosage forms and method of using same
Jul, 2016

(8 years ago)

Expired
US6645988 Substituted benzimidazole dosage forms and method of using same
Jul, 2016

(8 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Zegerid's patents.

Given below is the list of recent legal activities going on the following patents of Zegerid.

Activity Date Patent Number
Patent litigations
Correspondence Address Change 03 Nov, 2005 US6780882
Correspondence Address Change 28 Oct, 2005 US6780882
File Marked Found 23 Mar, 2005 US6780882
Correspondence Address Change 11 Mar, 2005 US6780882
File Marked Lost 04 Mar, 2005 US6780882
Correspondence Address Change 11 Nov, 2004 US6780882
Correspondence Address Change 27 Oct, 2004 US6780882
Patent Issue Date Used in PTA Calculation 24 Aug, 2004 US6780882
Recordation of Patent Grant Mailed 24 Aug, 2004 US6780882
Issue Notification Mailed 05 Aug, 2004 US6780882

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Zegerid is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Zegerid's family patents as well as insights into ongoing legal events on those patents.

Zegerid's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Zegerid's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 16, 2016 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Zegerid Generics:

There are no approved generic versions for Zegerid as of now.

Alternative Brands for Zegerid

Zegerid which is used for treatment of upper gastrointestinal issues including ulcers, GERD symptoms, and maintenance of esophagitis healing., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Azurity
Konvomep Used for reducing the risk of upper gastrointestinal bleeding and short-term treatment of active benign gastric ulcers in critically ill patients.
Santarus
Magnesium Hydroxide And Omeprazole And Sodium Bicarbonate Used for treating various gastrointestinal conditions such as ulcers, heartburn, and GERD.





About Zegerid

Zegerid is a drug owned by Santarus Inc. It is used for treatment of upper gastrointestinal issues including ulcers, GERD symptoms, and maintenance of esophagitis healing. Zegerid uses Magnesium Hydroxide; Omeprazole; Sodium Bicarbonate as an active ingredient. Zegerid was launched by Santarus in 2006.

Approval Date:

Zegerid was approved by FDA for market use on 24 March, 2006.

Active Ingredient:

Zegerid uses Magnesium Hydroxide; Omeprazole; Sodium Bicarbonate as the active ingredient. Check out other Drugs and Companies using Magnesium Hydroxide; Omeprazole; Sodium Bicarbonate ingredient

Treatment:

Zegerid is used for treatment of upper gastrointestinal issues including ulcers, GERD symptoms, and maintenance of esophagitis healing.

Dosage:

Zegerid is available in tablet, chewable form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
700MG;40MG;600MG TABLET, CHEWABLE Discontinued ORAL
700MG;20MG;600MG TABLET, CHEWABLE Discontinued ORAL